Pioneering Partnerships And Novel Trial Design Are Reshaping Repurposing In The CNS Space

Major Repurposing Projects Are Underway Across Multiple Disease Areas

Repurposing licensed drugs can be an affordable and effective way to bring new treatments to market, but initial efforts tend to lack funding from big pharma. In Vivo takes a closer look at repurposing projects across the central nervous system space, what it is that drives the work forward and how innovative trial design is changing the game.

Outstretched hands holding one red and one blue pill in each
• Source: Shutterstock

Highly anticipated results from the US National Institutes of Health’s Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) initiative proved disappointing for the research community in October last year, as the study revealed that sildenafil and tadalafil were not suitable candidates for treating dementia.

NIH researchers examined the risk of Alzheimer’s and related dementias using two groups of Medicare beneficiaries with pulmonary atrial hypertension;...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.